Collegium
COLL
Collegium (COLL) news
Recent news
Collegium Pharmaceutical, Inc.: Truist Securities cuts target price to $49 from $58
AInvest Wire · Sep 9, 2026Collegium Pharmaceutical, Inc.: Leerink partners initiates coverage with outperform rating; price target $45
AInvest Wire · Sep 9, 2026Collegium Pharmaceutical Q2 adjusted EPS USD 1.92 vs. IBES estimate USD 1.72
Collegium Pharmaceutical (COLL) reported second-quarter adjusted earnings per share (EPS) of USD 1.92, exceeding the IBES estimate of USD 1.72, according to recent financial results. The company also posted Q2 revenue of USD 188 million, surpassing the IBES revenue forecast of USD 180.9 million.…
AInvest Wire · Aug 6, 2026Collegium Pharmaceutical outlook FY revenue USD 825-855 million
AInvest Wire · Aug 6, 2026Coll sees FY adj. EBITDA $445M to $470M, saw $475M to $500M
AInvest Wire · Aug 6, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.